Abstract：Objective To explore the efficacy of radiotherapy combined with Gefitinib in the comprehensive treatment of elderly advanced non-small cell lung cancer (NSCLC). Methods A total of 82 elderly patients with advanced NSCLC admitted to Rugao Hospital Affiliated to Nantong University from November 2016 to December 2019 were selected and divided into control group (three-dimensional conformal radiotherapy, 41 cases) and observation group (three-dimensional conformal radiotherapy and Gefitinib, 41 cases) according to random number table method. After three months of continuous treatment, the short-term efficacy and the differences of tumor markers before and after treatment were compared between the two groups. The incidence of adverse reactions in the two groups was recorded. The two groups were followed up for one year, and the prognosis was compared by survival analysis. Results The short-term efficacy of observation group was better than control group, and the difference was statistically significant (P ＜ 0.05). The levels of serum cancer antigen 12-5, cancer antigen 15-3, and carcinoembryonic antigen in two groups were lower than those before treatment, and the observation group was lower than the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). The survival of observation group was better than control group, the difference was statistically significant (P ＜ 0.05). Conclusion Radiotherapy combined with Gefitinib can improve the short-term efficacy and 1-year survival situation of elderly patients with advanced NSCLC, and reduce the level of tumor markers, which is worthy of clinical promotion.
[1] 尚华，王艳美，张晕生.不同方案治疗局部晚期NSCLC对疾病控制及安全性分析[J].临床肺科杂志，2018，23（5）：802-805.
[2] 佘华龙，陈凯.表皮生长因子受体酪氨酸激酶抑制剂联合125I放射性粒子植入治疗非小细胞肺癌的效果[J].中国医药导报，2020，17（8）：4-10.
[3] 谭志巍，何弢，程双华，等.同步放化疗治疗Ⅲ期不可切除老年非小细胞肺癌患者的预后因素分析[J].老年医学与保健 2020，26（3），413-417.
[4] Rocco D，Della Gravara L，Battiloro C，et al. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer [J]. Expert Rev Anticancer Ther，2019，19（7）：561-568.
[5] 黄婉兰，陈宏鹏，林春平.吉非替尼靶向治疗EGFR阳性晚期非小细胞肺癌的疗效及对患者EGFR，Her-2，P-Akt和ERCC1的影响[J].海南医学，2020，31（11）：1373-1376.
[6] Ettinger DS，Wood DE，Akerley W，et al. Non-small cell lung cancer，version 1.2015 [J]. J Natl Compr Canc Netw，2014，12（12）：1738-1761.
[7] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45（2）：1-247.
[8] Hay JL，Atkinson TM，Reeve BB，et al. Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events（PRO-CTCAE）[J]. Qual Life Res，2014，23（1）：257-269.
[9] 武韫，吕帆真，吴越，等.循环肿瘤细胞形态学分析在老年非小细胞肺癌患者中的应用及其与预后相关的分析[J].老年医学与保健，2020，26（4）：640-643.
[10] Giustini NP，Jeong AR，Buturla J，et al. Advances in treatment of locally advanced or metastatic non-small cell lung cancer：targeted therapy [J]. Clin Chest Med，2020，41（2）：223-235.
[11] 戴秀梅，张有为，韩亮，等.安罗替尼治疗晚期非小细胞肺癌的临床效果[J].中国医药导报，2019，16（32）：8-12.
[12] Ko EC，Raben D，Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer [J]. Clin Cancer Res，2018，24（23）：5792-5806.
[13] 王辉.调强放疗联合吉非替尼靶向治疗NSCLC的效果观察[J].检验医学与临床，2020，17（6）：74-76，80.
[14] 徐佳欢，王新年，黄新，等.晚期非小细胞肺癌一线吉非替尼治疗后的耐药时间分析[J].实用药物与临床，2020，8（3）：21-23.
[15] 陈坤，雷杰，张志培，等.FGFR1通过调控PI3K/AKT/mTOR信号通路介导非小细胞肺癌对吉非替尼的耐药[J].现代生物医学进展，2019，19（2）：46-53.
[16] 汪蕾，汪芳，王茂玉.放疗联合吉非替尼治疗非小细胞肺癌患者的临床疗效[J].中国医师杂志，2020，22（9）：1392-1395.
[17] Chen ZQ，Huang LS，Zhu B. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer [J]. Dis Markers，2018，11（6）：98-103.
[18] 陈雯微.血清CEA、CA125及Cyfra21-1水平与中晚期非小细胞肺癌患者的临床特征与预后相关性分析[J].中国医师杂志，2019，21（11）：1714-1716.
[19] Shi Y，Li SS，Liu DY，et al. Cutaneous metastases of pancreatic carcinoma to the labia majora：A case report and review of literature [J]. World J Gastrointest Oncol，2020，12（11）：1372-1380.
[20] 付小玲，陈锟，徐佳学，等.非小细胞肺癌脑膜转移患者的脑脊液临床特征分析[J].检验医学，2018，33（8）：5-10.
[21] Nam SE，Lim W，Jeong J，et al. The prognostic significance of preoperative tumor marker（CEA，CA15-3）elevation in breast cancer patients：data from the korean breast cancer society registry [J]. Breast Cancer Res Treat，2019，177（3）：669-678.
[22] 陈坚，王棣，向小俐，等.血清TK1，CD147，VEGF，CYFRA21-1和CEA联合检测对非小细胞肺癌的诊断价值研究[J].标记免疫分析与临床，2019，26（7）：18-23.
[23] 武小玲，杨瑜，马高见，等.靶向药物阿帕替尼辅助三维适形调强放疗治疗老年非小细胞肺癌患者的临床效果[J].中国当代医药，2020，27（33）：9-12.
[24] 张泽良，俞杞泉，包琪，等.清热解毒方剂联合125I粒子植入治疗局限中晚期NSCLC疗效及对T细胞亚群和血清CEA等因子的影响[J].现代肿瘤医学，2019，27（10）：1741-1744.
[25] 谢馨，陈康彪，叶妍妍，等.吉非替尼治疗EGFR突变晚期肺腺癌的疗效与安全性研究[J].中国医药科学，2020， 10（8）：237-240.
[26] 高岭，杨增强，李宁，等.放疗联合吉非替尼治疗局部晚期非小细胞肺癌疗效观察[J].现代肿瘤医学，2018，26（16）：2529-2532.
[27] 林丽平，谢学军，郭玛丽.吉非替尼联合三维适形放疗治疗老年局部晚期非小细胞肺癌的疗效及对血清标志物的影响[J].中国医药科学，2020，10（24）：201-204.
[28] 孙岩萍，牛润桂，刘晓学，等.吉非替尼一线、二线治疗表皮生长因子受体不同位点突变的晚期非小细胞肺癌效果分析[J].肿瘤研究与临床，2019，31（5）：5-10.
京公网安备 11010502046598号